UT Health Science Center’s Liza Makowski, PhD, Helps Lead Global Conversation on GLP-1 Drugs and Cancer Risk
|Blockbuster drugs like Ozempic, Wegovy, and Zepbound have transformed obesity care for millions of Americans, making them some of the most talked-about medical breakthroughs of the decade. Yet several questions remain, including their long-term effects on cancer risk. A new commentary co-authored by Professor Liza Makowski, PhD, associate director for Education and Development in the… Read More







